- 英文名称
- Vinflunine Tartrate
- 分子式
- C49H60F2N4O14
- 分子量
- 967.02
- 中文别名
- 长春氟宁酒石酸盐; L-tartaric acid; (2R,3R)-2,3-Dihydroxybutanedioic acid;methyl (1R,9R,10S,11R,12R,19R)-11-acetyloxy-4-[(12S,14R,16R)-16-(1,1-difluoroethyl)-12-methoxycarbonyl-1,10-diazatetracyclo[12.3.1.03,11.04,9]octadeca-3(11),4,6,8-tetraen-12-yl]-12-ethyl-10-hydroxy-5-methoxy-8-methyl-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6,13-tetraene-10-carboxylate; (2R,3R)-2,3-dihydroxybutanedioic acid;methyl (1R,9R,10S,11R,12R,19R)-11-acetoxy-4-[(12S,14R,16R)-16-(1,1-difluoroethyl)-12-methoxycarbonyl-1,10-diazatetracyclo[12.3.1.03,11.04,9]octadeca-3(11),4,6,8-tetraen-12-yl]-12-ethyl-10-hydroxy-5-methoxy-8-methyl-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6,13-tetraene-10-carboxylate; (2R,3R)-2,3-Dihydroxybutanedioic acid--methyl 4beta-(acetyloxy)-15-[(4R,6R,8S)-4-(1,1-difluoroethyl)-8-(methoxycarbonyl)-1,3,4,5,6,7,8,9-octahydro-2,6-methanoazecino[4,3-b]indol-8-yl]-3beta-hydroxy-16-methoxy-1-methyl-2beta,5alpha,12beta,19alpha-6,7-didehydroaspidospermidine-3alpha-carboxylate (1/1); (2R,3R)-2,3-Dihydroxybutanedioic acidamethyl 4beta-(acetyloxy)-15-[(4R,6R,8S)-4-(1,1-difluoroethyl)-8-(methoxycarbonyl)-1,3,4,5,6,7,8,9-octahydro-2,6-methanoazecino[4,3-b]indol-8-yl]-3beta-hydroxy-16-methoxy-1-methyl-2beta,5alpha,12beta,19alpha-6,7-didehydroaspidospermidine-3alpha-carboxylate (1:1); Aspidospermidine-3-carboxylic acid, 4-(acetyloxy)-6,7-didehydro-15-[(2R,4R,6S,8S)-4-(1,1-difluoroethyl)-1,3,4,5,6,7,8,9-octahydro-8-(methoxycarbonyl)-2,6-methano-2H-azecino[4,3-b]indol-8-yl]-3-hydroxy-16-methoxy-1-methyl-, methyl ester, (2β,3β,4β,5α,12R,19β)-, (2R,3R)-2,3-dihydroxybutanedioate (1:x); Aspidospermidine-3-carboxylic acid, 4-(acetyloxy)-6,7-didehydro-15-[(2R,4R,6S,8S)-4-(1,1-difluoroethyl)-1,3,4,5,6,7,8,9-octahydro-8-(methoxycarbonyl)-2,6-methano-2H-azecino[4,3-b]indol-8-yl]-3-hydroxy-16-methoxy-1-methyl-, methyl ester
- 用途
- 长春氟宁酒石酸盐（vinfluninetartrate，VT）是由法国Pierre Fabre公司开发的新型半合成长春花碱，通过抑制微管蛋白的细胞增殖发挥抗肿瘤作用，用于治疗膀胱癌、非小细胞肺癌、乳腺癌和卵巢癌等。VT与酒石酸长春瑞滨的区别在于C-20'位上由两个氟原子取代两个氢原子，在人和鼠类13种肿瘤模型的体外抗癌实验中发现，VT比酒石酸长春瑞滨具有更好的抗癌活性和较小的神经毒性，但仍存在一定的剂量限制性毒性反应。脂质体作为一种靶向给药剂型，可改变药物的体内分布，降低药物的毒性及不良反应，提高药物治疗指数。
